Sodium-glucose co-transporter 2 inhibitors (SGLT2i); as a preventive factor of kidney failure in patients with type 2 diabetes; a meta-analysis of randomized controlled trials

Dorsa Jahangiri ^1,2 , Udit Narayan Padhi ³ , Henu Kumar Verma ⁴ , Bhaskar VKS Lakkakula ³ , Rohollah Valizadeh ^5,6 , Hamid Nasri ¹ *

Cited by CrossRef: 2

1- Cheng Q, Zou S, Feng C, Xu C, Zhao Y, Shi X, Sun M. Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. 2023;102(10):e33198 [Crossref]

2- Feng B, Yang F, Liu J, Sun Q, Meng R, Zhu D. Amelioration of diabetic kidney injury with dapagliflozin is associated with suppressing renal HMGB1 expression and restoring autophagy in obese mice. Journal of Diabetes and its Complications. 2023;37(3):108409 [Crossref]